Trial update
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1): registry status update
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.